HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

omecamtiv mecarbil

a cardiac myosin activator; structure in first source
Also Known As:
AMG-423; CK 1827452; CK-1827452
Networked: 115 relevant articles (16 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Malik, Fady I: 20 articles (05/2022 - 07/2010)
2. Teerlink, John R: 18 articles (05/2022 - 12/2009)
3. Dutta, Sandeep: 13 articles (01/2022 - 01/2021)
4. Lee, Edward: 13 articles (01/2022 - 01/2021)
5. Trivedi, Ashit: 13 articles (01/2022 - 01/2021)
6. Felker, G Michael: 12 articles (05/2022 - 03/2016)
7. McMurray, John J V: 11 articles (05/2022 - 03/2016)
8. Abbasi, Siddique: 11 articles (01/2022 - 12/2020)
9. Zhang, Hanze: 11 articles (01/2022 - 12/2020)
10. Metra, Marco: 10 articles (05/2022 - 03/2016)

Related Diseases

1. Heart Failure
2. Systolic Heart Failure
3. Left Ventricular Dysfunction
4. Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
01/01/2022 - "Introduction: Mavacamten (MAVA), Blebbistatin (BLEB), and Omecamtiv mecarbil (OM) are promising drugs directly targeting sarcomere dynamics, with demonstrated efficacy against hypertrophic cardiomyopathy (HCM) in (pre)clinical trials. "
09/01/2023 - "Cardiac myosin stimulator, omecamtiv mecarbil, has shown efficacy in HFrEF, lowering HF related events or cardiovascular death, while the 2 inhibitors, mavacamten and aficamten have been shown to reduce hypercontractility and left ventricular outflow obstruction improving functional capacity in randomized trials targeting hypertrophic cardiomyopathy. "
01/01/2022 - "In cardiac patients, a cardiac myosin stimulator, omecamtiv mecarbil, has shown efficacy in heart failure with reduced systolic function, lowering heart failure related events or cardiovascular death, while two inhibitors, mavacamten and aficamten, in randomized trials targeting hypertrophic cardiomyopathy, have been shown to reduce hypercontractility and left ventricular outflow obstruction improving functional capacity. "
12/01/2019 - "To produce and validate myofilament-restricted Ca2+ imaging probes in an adenoviral transduction adult cardiomyocyte model using drugs that alter myofilament function (MYK-461, omecamtiv mecarbil, and levosimendan) or following cotransduction of 2 established hypertrophic cardiomyopathy disease-causing mutants (cTnT [Troponin T] R92Q and cTnI [Troponin I] R145G) that alter myofilament Ca2+ handling. "
09/01/2023 - "This state-of-the-art review discuss the available evidence on the use of novel treatments of hypertrophic cardiomyopathy such as omecamtiv mecarbil, EMD-57033, levosimendan, pimobendan, and mavacamten for the treatment of heart failure (HF) in the context of guideline-directed medical therapy (GDMT). "
5. Left Ventricular Outflow Obstruction

Related Drugs and Biologics

1. Cardiac Myosins
2. MYK-461
3. Myosins (Myosin)
4. Brain Natriuretic Peptide (Natrecor)
5. vericiguat
6. Sodium-Glucose Transport Proteins
7. blebbistatin
8. Digoxin (Digitek)
9. Troponin
10. Tablets

Related Therapies and Procedures

1. Therapeutics
2. Cardiac Resynchronization Therapy
3. Denervation
4. Withholding Treatment
5. Stents